Using an additional test in patients who are not at high enough risk of developing disease to confidently treat, or low enough risk to confidently not treat would seem to be a straightforward way to resolve the clinical equipoise and is recommended by many guidelines. However, clear methods for evaluating the population utility of additional tests in this group have not been established. This paper includes worked examples and simulation data to show that focus on the intermediate risk group alone can be misleading and that population utility is best evaluated across the full range of risk.
Decisions about treatment attempt to best balance risks and benefits, with estimation of the risk of disease prior to treatment playing a critical role in that process at both the individual and the population level. Though there is rarely a perfect threshold of risk for action, guidelines in multiple settings have arrived at useful risk cut points to inform treatment decisions. These cut points often result in three implicit or explicit strata: risk high enough to confidently treat, risk low enough to confidently not treat, and those in between, or the "intermediate risk" group. Though at the individual level, this clinical equipoise may be resolved with a discussion between doctor and patient, from a guideline perspective, the recommendation might include subsequent testing that can appropriately reclassify people into a low risk or high risk stratum and improve prediction at a population level. However, in contrast with evaluating a new marker for inclusion in the overall risk model, the process for evaluating prediction improvement in the intermediate risk group is not well developed.
Case study: cardiovascular disease risk Risk prediction is a widely discussed tool in the prevention of cardiovascular disease and treatment of related risk factors, such as cholesterol. Current guidelines estimate risk of future cardiovascular disease events, using a risk score such as QRISK2 1 or the pooled cohort equations, 2 to guide treatment decisions. The joint American College of Cardiology and American Heart Association guidelines on the treatment of cholesterol, 3 use a threshold of 7.5% 10 year cardiovascular disease risk to identify a subset of high risk people who might benefit from statin treatment. They also implicitly create an intermediate risk stratum of people from 5% up to 7.5% 10 year risk for potential treatment and suggest that additional factors or tests, such as family history, C reactive protein level, or coronary artery calcium score might be considered as part of individual clinician-patient discussions and decision making. Similarly, the UK National Institute for Health and Care Excellence guidelines 4 use a threshold of 10% 10 year risk to identify high risk people for treatment and direct clinicians to take additional factors or tests into account in treatment decisions when risk is near the threshold. The Joint British Societies' consensus recommendations 5 7 ). There have also been trials randomizing people at intermediate risk to receive additional information, such as a genetic risk score. 8 We propose a strategy for research and evaluation of new markers for the intermediate risk group (see box 1). These are illustrated using results of a simulation study based on cardiovascular disease risk, as well as an example using real data, to highlight the consequences of different analytic choices. Our results are based on the assumption that the association between the outcome and the new test is no different in the intermediate risk group from that in the full population. • Estimation of the model in which the new test is evaluated in the full population rather than the intermediate risk group alone
Example with a true association
• Use of the full population to estimate the expected prediction improvement under the null
• Presentation of both the observed and the expected prediction improvement, or a bias correction in the case of the net reclassification improvement, in the interpretation of the overall impact
Consider a sample of the full population if a smaller study is necessary score and evaluates high density lipoprotein cholesterol as a new marker in the Women's Health Study (see box 2 for additional details). As outlined in our proposed method, the first step is to estimate a risk model that includes both the new marker and the components of the established score in the full population. In such nested models, the most efficient and reliable test of independent improvement in prediction is the coefficient for the new marker. 9 We evaluate the coefficient for the natural log of high density lipoprotein cholesterol from the model, which is statistically significant (P<0.001) when calculated in the full data. If, instead, we had used only those participants in the intermediate risk group from the established model to estimate our model, the coefficient for high density lipoprotein cholesterol would not be significant (P=0.13), likely due to a smaller sample size as well as a more limited range for the predictor variables. Given a significant coefficient, the next step is to examine additional measures of clinical utility. In light of our setting of established risk strata, with new tests being considered only for those at intermediate risk, we focus primarily on measures that incorporate these risk strata. For simplicity we also focus on binary events, where the outcome is known at a specific time pointfor example, at 10 years-though many of the methods discussed have been extended to the setting of survival models.
One simple metric of change in prediction for the intermediate risk group is the probability of cases and non-cases being reassigned to the high risk or low risk groups, similar to the sensitivity and specificity of the new marker. In our example, adding high density lipoprotein to the model calculated using all the data, reclassified 27% of the initially intermediate risk cases over the threshold into high risk. However, it also reclassified 20% of the non-cases into the high risk group.
However, some movement would be expected even with a marker not associated with cardiovascular disease. Since the full range of data are available, a table of the expected changes in predicted risk if there were no association can be calculated and used to generate an estimate of the expected value for each of the prediction measures. 10 We outline this method in fig 1 . Now each measure can be compared with its expected value to obtain a clearer picture of the actual improvement, as shown in with one adding homocysteine (a historical candidate risk factor) using a similar framework • The reclassification used the eight year equivalents (<4%, 4% to <6%, and ≥6%) of the joint American College of Cardiology and American Heart Association 10 year risk strata (<5%, 5% to <7.5%, ≥7.5%). Models were run using the entire dataset and then rerun only in the participants with predicted intermediate risk values using the initial model (without the new marker) lipoprotein cholesterol to the model does reclassify more cases to the high risk stratum than expected, though the effect above chance is small (5%). Also, fewer cases than expected are reclassified to the low risk stratum. The observed movement is larger when the model is derived only in the intermediate risk group, and the expected movement then cannot be calculated. The net reclassification improvement 11 summarizes whether cases have a higher probability of moving to a higher risk stratum than to a lower risk stratum and non-cases have a higher probability of moving to a lower risk stratum than to a higher risk stratum. The same strategy can be used among those who start at intermediate risk. While the expected value for the net reclassification improvement overall is 0 if there is no association we have previously shown that substantial bias may occur if the net reclassification improvement is calculated only for the intermediate group and not corrected using the method from fig 1 . 10 In the full data for high density lipoprotein cholesterol, the net reclassification improvement for the intermediate risk group alone has a 95% bootstrap confidence interval (0.05 to 0.33) that does not include 0, suggesting improvement in prediction. However, the 95% confidence interval for the bias corrected net reclassification improvement (observed minus expected) of (−0.10 to −0.18) does include 0, and the estimated effect is lower.
To compare the observed risk in each stratum to the average predicted risk, a reclassification calibration test can also be performed, with a significant P value suggesting a lack of fit. 12 Like the net reclassification improvement, it is usually performed on the whole 
Example with no association
Our second example, shown in table 2, uses a model without homocysteine as the existing score and evaluates homocysteine as a new marker. In this example, the coefficient for homocysteine was not significant when the full population was used for model estimation or when only the group identified as intermediate risk by the established model was used. Though this confirms the importance of using the coefficient as the initial test of association, we present all the results for discussion. For all of the measures, estimates obtained from the models in the full population are consistent with the non-significant coefficient. However, the results are noticeably different when using the participants at intermediate risk for model development.
Model without HDL
Based on this table, the probability of cases categorized as intermediate risk by the model without HDL moving to the high risk stratum would be /( + + ) = .
. Similarly, the crude reclassi cation improvement (RI) for intermediate risk cases would be ( -)/( + + ) = .
Once the expected table is generated, it can be used to calculate the expected values for any prediction measure. For example, the expected probability of cases categorized as intermediate risk by the model without HDL moving to the high risk stratum would be . /( . + + . ) = . The results for the expected values under the null can be subtracted from the crude measures to correct the measures in the intermediate risk group. The bias corrected RI for cases is .
-. = .
, and the bias corrected RI for non-cases is .
-. = -. The bias corrected NRI is then .
-. (= .
-. ) = . And calculate the expected table as follows: Many other excellent measures of prediction exist, including the difference in the C statistic, the integrated discrimination improvement, and continuous net reclassification improvement, among others. These measures are an important part of the overall presentation and should be incorporated when evaluating the risk prediction performance of a new marker. In supplemental 
